Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084923" target="_blank" >RIV/00023001:_____/24:00084923 - isvavai.cz</a>
Result on the web
<a href="https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15609" target="_blank" >https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15609</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/dom.15609" target="_blank" >10.1111/dom.15609</a>
Alternative languages
Result language
angličtina
Original language name
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
Original language description
Fixed-ratio combinations of a basal insulin and a glucagon-likepeptide-1 receptor agonist (GLP-1RA) have recently been incorporatedin the latest US and European guidelines for the management ofpeople with inadequately controlled type 2 diabetes (T2D), and glycatedhaemoglobin (HbA1c) >2% above target or HbA1c value >10%(>85.8 mmol/mol). In addition to their effect on glycaemic control,the combination of a GLP-1RA and basal insulin in one injection mitigatesthe side effects of its individual components, such as the gastrointestinaladverse events (AEs), associated with GLP-1RAs and theweight gain associated with insulin use.iGlarLixi is the fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and the GLP-1RA lixisenatide (Lixi), administered subcutaneouslyonce daily within 1 h before the most convenient meal.Although treatment with iGlarLixi achieved favourable clinical resultsin randomized controlled trials (RCTs), there are still limited dataon the real-life effectiveness and safety of initiating iGlarLixi ininsulin-naïve versus insulin-pretreated people with T2D.We have pooled data, therefore, from two observational studiesto evaluate the treatment outcomes of iGlarLixi in people withT2D inadequately controlled on non-insulin glucose-lowering therapy,with or without basal insulin, in the real-life setting.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes, obesity and metabolism
ISSN
1462-8902
e-ISSN
1463-1326
Volume of the periodical
26
Issue of the periodical within the volume
7
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
2988-2992
UT code for WoS article
001216677500001
EID of the result in the Scopus database
2-s2.0-85191995772